Institute for Clinical and Economic Review (ICER) Review of Disease-Modifying Therapies and Addendum

On July 18, the Institute for Clinical and Economic Review (ICER) announced that it would expand its review of multiple sclerosis disease-modifying therapies (DMTs) to include potential therapies for progressive MS. View the Society's comments; the public comment period for this addendum closed on August 12. On July 15, the National MS Society submitted comments to ICER in response to its draft scope to review disease-modifying therapies used to treat relapsing-remitting MS. ICER assesses the value of medications by considering price, how well a medication works compared to others, quality…

Favicon of da :

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati